Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19: Facts and Open Questions

J Am Coll Cardiol. 2022 Oct 4;80(14):1363-1365. doi: 10.1016/j.jacc.2022.08.003.

¹ Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht University, Maastricht, the Netherlands; Department of Cardiovascular Sciences, Leuven University, Leuven, Belgium. Electronic address: s.heymans@maastrichtuniversity.nl.
² School of Medicine and Dentistry, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom.
³ Mount Sinai Heart, Mount Sinai Hospital, New York, New York, USA; Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.
⁴ Institute of Cardiology, Civil Hospital, University of Brescia, Brescia, Italy.
⁵ Cardio-Oncology Unit, Department of Translational Medical Sciences, Center for Basic and Clinical Immunology Research, Interdepartmental Center of Clinical and Translational Sciences, Interdepartmental Hypertension Research Center, University of Naples Federico II, Naples, Italy.

No abstract available

Keywords: COVID-19; myocarditis; vaccination.

MeSH terms